- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- MedEspera: International Medical Congress for Students and Young Doctors
- MedEspera 2020
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/11897
Title: | Placebo and nocebo effects - a synthesis of main underlying mechanisms |
Authors: | Rusu, Ghenadie |
Keywords: | placebo effect;nocebo effect;response expectancy;unconditioned factors;placebo genetics |
Issue Date: | 2020 |
Publisher: | MedEspera |
Citation: | RUSU, Ghenadie. Placebo and nocebo effects - a synthesis of main underlying mechanisms. In: MedEspera: the 8th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2020, p. 261-262. |
Abstract: | Introduction. Although the effects of placebo have been known in medicine for several
centuries, the research of the underlying mechanisms has developed relatively recently.
Consequently, in the last decades, numerous studies and researches have been published, most
of them focused on symptoms such as pain, fatigue, nausea and itching.
Aim of the study. To disclosure the main mechanisms underlying the placebo and nocebo
effects.
Materials and methods. The study was performed in the base of reviewes of various
researches and scientific materials (articles in specialized journals, monographs and articles on
the Internet etc.) that refer to placebo/nocebo effects description and observation.
Results. The classical conditioning theory and the response expectancy model were considered
for a long time the most accepted theories explaining the underlying processes of
placebo/nocebo phenomena. Numerous researches revealed that suggestions, thoughts and
beliefs could have an important influence on human body, thus giving rise to specific
therapeutic processes. However, placebo and nocebo effects are not mediated only by
psychological mechanisms. There is a clear evidence of neurobiological changes at different
levels and areas of the brain, involving endogenous opioids, as well as dopamine, especially in
the case of the analgesic placebo effect. Similarly, such neuromodulators as cholecystokinin
play a significant role in the nocebo effect. The findings concerning the involvement of the
genetic mechanisms in the process of manifesting placebo/nocebo effects cannot be neglected.
In the last years, the studies reveal that genetic variations in the brain's neurotransmitter pathways could influence placebo effects, the incipient evidence being provided with regard to
existence of genes that mediate placebo effects in individual patients. Placebo/nocebo genetics
is an area in which research is only in a quit early phase.
Conclusions. The study results evoke the complexity of the placebo and implicitly nocebo
phenomena and the difficulty of formulating a generally valid theory, which could explain in a
clear and complete manner how they function. The described mechanisms have to be regarded
in a complementary manner and must be analyzed and regarded as a whole. It is worth to
continue the investigations of placebo/nocebo mechanisms so as to optimize the therapeutic
interventions and to improve the design of clinical trials. |
URI: | https://medespera.asr.md/wp-content/uploads/ABSTRACT-BOOK.pdf http://repository.usmf.md/handle/20.500.12710/11897 |
Appears in Collections: | MedEspera 2020
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|